AF
TARA icon

Allworth Financial’s Protara Therapeutics TARA Stock Holding History

Allworth Financial’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42K Buy
371
+288
+347% +$1.37K ﹤0.01% 4626
2026
Q1 		$433 Buy
+83
New +$491 ﹤0.01% 4766

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Allworth Financial's TARA Position: Q2 2026 in Review

Allworth Financial increased its Protara Therapeutics (TARA) stake by 347% in Q2 2026, buying an estimated $1.37K and bringing the position to 371 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #4626.

Allworth Financial first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Allworth Financial held 371 shares of Protara Therapeutics worth $1.42K as of Q2 2026.
  • Allworth Financial bought 288 Protara Therapeutics shares in Q2 2026, an estimated $1.37K.
  • Protara Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4626 holding.
  • Allworth Financial first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.